# NCT02242942 (NCT02242942)

> Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02242942
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Lymphocytic Leukemia, Chronic
- Interventions: Chlorambucil; Venetoclax; Obinutuzumab
- Enrollment: 445
- Primary outcome: Progression Free Survival (PFS) Based on Investigator Assessment According to IWCLL Criteria

## Commentary we found

- YouTube: 95
- Podcasts: 74
- X threads: 19
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nct02242942

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02242942", "email": "<work email>"}; the inbox owner confirms by the emailed link.